Fast Dissociating Dopamine D2 Antagonists for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotics for schizophrenia often cause motor side effects due to slow dissociation from dopamine D2 receptors, and they may also induce metabolic disorders and other adverse effects through interactions with various neurotransmitter receptors.
Innovation Solution
Development of piperazin-1-yl-trifluoromethyl-substituted-pyridines that act as fast dissociating dopamine 2 receptor antagonists with moderate affinity for dopamine D3 and serotonin 5-HT6 receptors, minimizing interactions with adrenergic α1, histamine H1, and serotonin 5-HT2C receptors to reduce motor side effects and metabolic risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotics block dopamine D2 receptors with high affinity, then antipsychotic efficacy is improved, but motor side effects increase due to slow dissociation from the receptor
Solution Approach 1:
The patent modifies the chemical structure of the antipsychotic compound by introducing a piperazin-1-yl group at the 1-position and a trifluoromethyl group at the 3-position of the pyridine ring. These structural parameter changes result in altered binding kinetics, specifically faster dissociation from dopamine D2 receptors, thereby reducing motor side effects while maintaining antipsychotic efficacy
Solution Approach 2:
The patent introduces specific substituent groups at defined positions on the pyridine ring structure. The piperazin-1-yl group at position 1 and trifluoromethyl group at position 3 create localized structural features that influence receptor interaction dynamics, enabling selective modulation of binding affinity and dissociation rate without compromising overall therapeutic effect
2Reliability
If antipsychotics interact with multiple neurotransmitter receptors, then cognitive and negative symptoms may be improved, but metabolic disorders and other adverse effects increase
Solution Approach 1:
The patent introduces specific substituent groups at defined positions on the pyridine ring structure. The piperazin-1-yl group at position 1 and trifluoromethyl group at position 3 create localized structural features that influence receptor interaction dynamics, enabling selective modulation of binding affinity and dissociation rate without compromising overall therapeutic effect
Solution Approach 2:
The patent describes compounds that simultaneously interact with multiple receptor types (dopamine D2, dopamine D3, serotonin 5-HT6, serotonin 5-HT2A) while maintaining a balanced pharmacological profile. This multi-functional interaction pattern addresses both cognitive/negative symptoms through selective receptor engagement and minimizes metabolic side effects through optimized binding characteristics across multiple target receptors
Data Source
AI summary
The present invention relates to piperazin-1-yl-trifluoromethyl-substituted-pyridines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. Formula (I).